BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-54@catalystbrief.girapphe.com
DTSTAMP:20261117T061551Z
LAST-MODIFIED:20261117T061551Z
DTSTART;VALUE=DATE:20261101
DTEND;VALUE=DATE:20261102
SUMMARY:Readout: EMD Serono Research & Development Institute\, Inc. — Ave
 lumab [Nov 2026]
DESCRIPTION:Phase 3 primary completion: Avelumab Program Rollover Study.\nS
 ource: https://clinicaltrials.gov/study/NCT03815643\nhttps://catalystbrief
 .girapphe.com/e/54?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/54?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
